ISRCTN76377555已完成未知
Bispectral (BIS) electroencephalogram (EEG) monitored sedation in intensive care unit (ICU) patients. A preliminary randomised controlled trial
Department of Health (UK)0 个研究点目标入组 0 人开始时间: 2003年9月12日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Postoperative cardiac surgery patients who are expected to have an uneventful postoperative recovery.
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryEUCTR2004-001128-19-DKBristol-Myers Squibb International Corporation1,666
已完成
不适用
2-Year Cerebral Performance Categories According To Initial Rhythm And Resuscitation Time Following In-Hospital Cardiac ArrestIn-Hospital Cardiac ArrestTwo-Year Cerebral Performance CategoriesACTRN12617001370392Konya Numune State Hospital44
进行中（未招募）
1 期
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001966-39-PLovartis Pharma AG234
进行中（未招募）
1 期
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001966-39-DKovartis Pharma AG234
进行中（未招募）
1 期
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001966-39-IEovartis Pharma AG234